Not one but two new studies published today have not linked GLP-1 drugs as ozepic with a reduced risk of developing dementia.
There is currently no cure for Alzheimer’s, which affects about 6.7 million Americans aged 65 and older, but study authors say these drugs can be used as a preventative measure against future illness.
This is only one by one a growing list of diseases and conditions that Ozepic has been found to improve or help prevent, from colorectal cancer to PCOS to substance abuse.
In one of the two new studies, published in Jama Neurology, researchers saw how the GLP-1-Medicine receptor agonists such as semaglutides, dulaglutides and liraglutides, which are sold as Ozepic, Trulicity and Victosis, respectively the risk of dementia in people with diabetes.
They also studied SGLT2 inhibitors such as jardiance (empagliflozin) and farxiga (dapagliflozine), which are also used to treat diabetes.
They found that taking one of these drug classes was “significantly associated with a reduced risk of Alzheimer’s disease and related dementia,” said Dr. Jingchuan Guo, one of the authors of the study.
“Exciting exciting these drugs for diabetes can provide additional benefits, such as protecting brain health,” Guo Post told. “While the use of GLP-1 (GLP-1ra) receptor agonists continues to expand, it becomes increasingly important to understand their real-world benefits and dangers in different populations.”
Meanwhile, an analysis of 26 rehearsals-with a total of 164,531 participants-also published in Jama Neurology Today had similar findings, linking GLP-1 drugs with a 45% lower risk of dementia.
“This research represents an important contribution to our understanding of how glucose reducing medicines can affect brain health,” said study co -author Dr. Catriona Reddin for the post.
“Diabetes is a well-known risk factor for dementia, but if glucose reducing therapies can help prevent cognitive fall has remained unclear … Our findings suggest that the GLP-1 receptor agonists, in particular, are related to the reduced risk of dementia.”
Both studies focused specifically on patients with type 2 diabetes. For Guo and her team, this is partly because they used data that goes back to 2014, when these treatments were almost exclusively described.
“While some new GLP-1ra … have recently been approved for overweight treatment, their wide use for this indicator began only in recent years,” she explained.
Moreover, diabetics tend to be at greater risk for Alzheimer because high blood sugar can damage the blood vessels in the brain and cause inflammation. Obesity has also been associated with chronic inflammation.
Neuroinflammation – inflammation of the nerve tissue – is often observed in Alzheimer’s patients.
Guo noted that “another important step” is to see how these medicines affect people without type 2 diabetes.
Both researchers see the possibility that these drugs are used as Alzheimer’s prevention in the future, though they point out that more studies are needed.
“Posible possible for them to play a role as a preventative measure in the future,” Reddin said. “However, great evidence must be made to specifically study the effect of the therapy on lowering glucose on dementia and cognitive decline. There are a number of evidence that continues to see the effect of glucose reducing recognition.”
In October, researchers determined that Semaglutide reduced the risk of Alzheimer’s from people with diabetes more than seven other diabetes drugs.
“Parachinical research has suggested that semaglutide can protect against neurodegeneration and neuroinflammation,” said the Biomedical Information Professor of the Case Western Reserve Reserve Rong XU.
#Weight #loss #drugs #ozmepic #risk #dementia
Image Source : nypost.com